Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
Despite the benefits of red blood cell (RBC) transfusion therapy, it can render patients vulnerable to iron overload. The excess iron deposits in various body tissues cause severe complications and organ damage such as cardiotoxicity and mold infections. infection (CDI) is the most common cause of n...
Gespeichert in:
Veröffentlicht in: | Antibiotics (Basel) 2022-04, Vol.11 (5), p.537 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Despite the benefits of red blood cell (RBC) transfusion therapy, it can render patients vulnerable to iron overload. The excess iron deposits in various body tissues cause severe complications and organ damage such as cardiotoxicity and mold infections.
infection (CDI) is the most common cause of nosocomial diarrhea among cancer patients and is associated with significant morbidity and mortality. Our study aims to determine the role of iron overload and the effects of iron chelators on CDI. Our results demonstrated that iron (Fe
) stimulated the growth of
with increased colony formation units (CFU) in a dose-dependent manner. Exposure to excess iron also increased the gene expression levels of
and
. The production of
toxin A, necessary for the pathogenesis of
, was also elevated after iron treatment. In the presence of excess iron,
becomes less susceptible to metronidazole with significantly elevated minimum inhibitory concentration (MIC) but remains susceptible to vancomycin. Iron-stimulated colony formation and production of
toxins were effectively diminished by iron chelator deferoxamine co-treatment. Incorporating iron overload status as a potential factor in developing a risk prediction model of CDI and antibiotic treatment response may aid clinical practitioners in optimizing CDI management in oncology patients. |
---|---|
ISSN: | 2079-6382 2079-6382 |
DOI: | 10.3390/antibiotics11050537 |